Rapid Micro Biosystems, Inc. (RPID) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RPID Revenue Growth
Revenue Breakdown (FY 2025)
RPID's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RPID Revenue Analysis (2019–2025)
As of May 8, 2026, Rapid Micro Biosystems, Inc. (RPID) generated trailing twelve-month (TTM) revenue of $30.5 million, reflecting modest growth of +3.1% year-over-year. The most recent quarter (Q3 2025) recorded $7.8 million in revenue, up 7.9% sequentially.
Looking at the longer-term picture, RPID's 5-year compound annual growth rate (CAGR) stands at +15.9%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $33.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RPID's business is primarily driven by Product (72%), and Service (28%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IDXX (+13.1% YoY), NEOG (-3.7% YoY), and BRKR (+0.4% YoY), RPID has underperformed the peer group in terms of revenue growth. Compare RPID vs IDXX →
RPID Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RPIDCurrent | $31M | +3.1% | +15.9% | -141.1% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% | |
 BRKR | $3.4B | +0.4% | +11.6% | 6.9% | |
 AZTA | $594M | +1.8% | +8.9% | -1.9% | |
 BIO | $2.6B | +1.9% | +0.3% | 10.5% |
RPID Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $33.6M | +19.7% | $7.6M | 22.7% | $-47,392,000 | -141.1% |
| 2024 | $28.1M | +24.6% | $-109,000 | -0.4% | $-49,919,000 | -178.0% |
| 2023 | $22.5M | +31.4% | $-5,485,000 | -24.4% | $-56,563,000 | -251.2% |
| 2022 | $17.1M | -26.3% | $-8,540,000 | -49.8% | $-63,219,000 | -369.0% |
| 2021 | $23.2M | +44.5% | $-7,741,000 | -33.3% | $-47,232,000 | -203.3% |
| 2020 | $16.1M | -2.6% | $-8,071,000 | -50.2% | $-30,540,000 | -190.0% |
| 2019 | $16.5M | - | $-234,000 | -1.4% | $-18,634,000 | -112.9% |
See RPID's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RPID Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RPID vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRPID — Frequently Asked Questions
Quick answers to the most common questions about buying RPID stock.
Is RPID's revenue growth accelerating or slowing?
RPID revenue growth slowed to +3.1%, below the 5-year CAGR of +15.9%. TTM revenue is $31M. The deceleration marks a shift from historical growth rates.
What is RPID's long-term revenue growth rate?
Rapid Micro Biosystems, Inc.'s 5-year revenue CAGR of +15.9% reflects the variable expansion pattern. Current YoY growth of +3.1% is near this long-term average.
How is RPID's revenue distributed by segment?
RPID reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.